 | |
| Formerly | Inhale Therapeutic Systems, Inc. |
|---|---|
| Company type | Public |
| Industry | Biopharmaceuticals |
| Founded | 1990 |
| Headquarters | San Francisco, California, U.S. |
| Products | |
| Revenue | US$90.1million (2023)[1] |
Number of employees | 137 (2024) |
| Website | nektar |
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.[2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances[3], which improves drug characteristics like retention and solubility.[4] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.[2] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.[5]
- ^ "Nektar Therapeutics".
- ^ a b "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
- ^ "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
- ^ Kansteiner, Fraiser (2024-11-04). "Nektar extends cash runway with $90M manufacturing plant sale". www.fiercepharma.com. Retrieved 2024-12-19.
- ^ Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN 0099-9660. Retrieved 2020-01-22.